Sector Gamma AS Buys Shares of 740,671 Astrazeneca PLC (AZN)

Sector Gamma AS purchased a new stake in Astrazeneca PLC (NYSE:AZN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 740,671 shares of the company’s stock, valued at approximately $25,094,000. Astrazeneca PLC accounts for 3.8% of Sector Gamma AS’s investment portfolio, making the stock its 12th biggest holding.

Several other large investors have also recently made changes to their positions in the business. Fisher Asset Management LLC increased its stake in shares of Astrazeneca PLC by 4.7% in the third quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after purchasing an additional 519,717 shares during the period. Federated Investors Inc. PA increased its stake in shares of Astrazeneca PLC by 3.6% during the second quarter. Federated Investors Inc. PA now owns 4,484,770 shares of the company’s stock valued at $152,885,000 after acquiring an additional 156,256 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Astrazeneca PLC by 5.9% during the second quarter. Ameriprise Financial Inc. now owns 2,827,262 shares of the company’s stock valued at $96,789,000 after acquiring an additional 157,293 shares during the period. Voya Investment Management LLC increased its stake in shares of Astrazeneca PLC by 38.2% during the second quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock valued at $81,661,000 after acquiring an additional 662,481 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Astrazeneca PLC by 5.5% during the second quarter. Dimensional Fund Advisors LP now owns 2,163,183 shares of the company’s stock valued at $73,743,000 after acquiring an additional 112,618 shares during the period. Institutional investors own 14.16% of the company’s stock.

AZN has been the topic of several recent research reports. Natixis upgraded shares of Astrazeneca PLC from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 6th. Argus restated a “buy” rating and issued a $35.00 price target on shares of Astrazeneca PLC in a research report on Friday, September 1st. Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. Finally, Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca PLC in a research report on Friday, September 22nd. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. Astrazeneca PLC presently has a consensus rating of “Hold” and a consensus price target of $34.20.

Astrazeneca PLC (NYSE:AZN) traded up $0.34 during trading hours on Wednesday, reaching $33.25. 2,914,200 shares of the company’s stock were exchanged, compared to its average volume of 4,841,029. The firm has a market capitalization of $82,760.00, a price-to-earnings ratio of 7.85, a PEG ratio of 2.84 and a beta of 0.79. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.55. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The firm had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the business earned $1.32 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. analysts expect that Astrazeneca PLC will post 1.93 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Sector Gamma AS Buys Shares of 740,671 Astrazeneca PLC (AZN)” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/11/15/sector-gamma-as-buys-shares-of-740671-astrazeneca-plc-azn.html.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply